Media Thread, page-5935

At 12 months, more patients treated with Enhertu were alive without disease progression compared with those treated with Kadcyla (75.8% versus 34.1%). When disease progression was taken out of consideration, 94.1% of patients in the Enhertu group were alive at 12 months compared with 85.9% of those in the Kadcyla group””


This however is impressive, blows pretty much anything approved or in trial out of the water.

524 patient phase 3 trial, now received approvals. Very impressive data and results. Owned by AstraZeneca




https://www.curetoday.com/view/enhertu-bests-standard-of-care-in-potentially-preventing-disease-progression-death-in-previously-treated-her2-positive-metastatic-breast-cancer